1 – 160 of 160
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders
(
- Contribution to journal › Article
-
Mark
Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort
2024) In Journal of Neurology(
- Contribution to journal › Article
-
Mark
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
Plasma N-terminal containing tau fragments (NTA-tau) : a biomarker of tau deposition in Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Plasma Biomarker Strategy for Selecting Patients with Alzheimer Disease for Antiamyloid Immunotherapies
(
- Contribution to journal › Article
-
Mark
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
(
- Contribution to journal › Article
-
Mark
Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests
2024) In Nature Medicine(
- Contribution to journal › Article
-
Mark
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
(
- Contribution to journal › Article
-
Mark
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
(
- Contribution to journal › Article
-
Mark
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
(
- Contribution to journal › Article
-
Mark
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer's disease
2024) In bioRxiv : the preprint server for biology(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
2024) In JAMA(
- Contribution to journal › Article
-
Mark
Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
(
- Contribution to journal › Article
-
Mark
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders : An International, Multicenter Study
(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
2024) In Nature Aging(
- Contribution to journal › Article
- 2023
-
Mark
CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers
(
- Contribution to journal › Article
-
Mark
The genetic regulation of protein expression in cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
Gray matter hypoperfusion is a late pathological event in the course of Alzheimer's disease
2023) In Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 43(4). p.565-580(
- Contribution to journal › Article
-
Mark
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma IAPP-Autoantibody Levels in Alzheimer’s Disease Patients Are Affected by APOE4 Status
(
- Contribution to journal › Article
-
Mark
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
(
- Contribution to journal › Article
-
Mark
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models
(
- Contribution to journal › Article
-
Mark
Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
(
- Contribution to journal › Article
-
Mark
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
(
- Contribution to journal › Article
-
Mark
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients : A multi-cohort study
(
- Contribution to journal › Article
-
Mark
Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes
(
- Contribution to journal › Article
-
Mark
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
(
- Contribution to journal › Article
-
Mark
Ultra-high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau
(
- Contribution to journal › Article
-
Mark
Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
(
- Contribution to journal › Article
-
Mark
Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Clinical effects of Lewy body pathology in cognitively impaired individuals
(
- Contribution to journal › Article
-
Mark
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
(
- Contribution to journal › Article
-
Mark
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors
(
- Contribution to journal › Article
-
Mark
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
(
- Contribution to journal › Article
-
Mark
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
(
- Contribution to journal › Article
- 2022
-
Mark
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
(
- Contribution to journal › Article
-
Mark
Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives
(
- Contribution to journal › Article
-
Mark
Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
(
- Contribution to journal › Article
-
Mark
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings
(
- Contribution to journal › Article
-
Mark
Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration
(
- Contribution to journal › Article
-
Mark
Association of CSF Aβ38Levels with Risk of Alzheimer Disease-Related Decline
(
- Contribution to journal › Article
-
Mark
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
(
- Contribution to journal › Article
-
Mark
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
(
- Contribution to journal › Article
-
Mark
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
A biomarker profile of elevated CSF p-tau with normal tau PET is associated with increased tau accumulation rates on PET in early Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus
(
- Contribution to journal › Article
-
Mark
β-Amyloid-Dependent and-Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
(
- Contribution to journal › Article
-
Mark
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum
(
- Contribution to journal › Article
-
Mark
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults : Effects of Alzheimer's Disease Pathology and Cognitive Decline
(
- Contribution to journal › Article
-
Mark
The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders
(
- Contribution to journal › Article
-
Mark
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
(
- Contribution to journal › Article
-
Mark
Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease : Long-Term Observation and Implications of Clinical Subtypes
(
- Contribution to journal › Article
-
Mark
Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers : Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
(
- Contribution to journal › Article
-
Mark
Blood-based biomarkers for Alzheimer's disease
(
- Contribution to journal › Scientific review
-
Mark
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers
(
- Contribution to journal › Article
- 2021
-
Mark
Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age
(
- Contribution to journal › Article
-
Mark
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
(
- Contribution to journal › Article
-
Mark
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
A multicentre validation study of the diagnostic value of plasma neurofilament light
(
- Contribution to journal › Article
-
Mark
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
(
- Contribution to journal › Article
-
Mark
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
(
- Contribution to journal › Article
-
Mark
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
(
- Contribution to journal › Article
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
(
- Contribution to journal › Article
-
Mark
Associations of Plasma Phospho-Tau217 Levels with Tau Positron Emission Tomography in Early Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease
(
- Contribution to journal › Article
-
Mark
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
(
- Contribution to journal › Article
-
Mark
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Genetic interaction study of Alzheimer's disease quantitative biomarkers : A polygenic risk score analysis and evaluation
(
- Contribution to journal › Article
-
Mark
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease
(
- Contribution to journal › Article
- 2020
-
Mark
Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration : A translatable marker of synaptic degeneration
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders
(
- Contribution to journal › Article
-
Mark
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease : a diagnostic performance and prediction modelling study using data from four prospective cohorts
(
- Contribution to journal › Article
-
Mark
The implications of different approaches to define AT(N) in Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
(
- Contribution to journal › Article
-
Mark
Plasma P-tau181 in Alzheimer’s disease : relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
(
- Contribution to journal › Article
-
Mark
Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype
(
- Contribution to journal › Article
-
Mark
Quantification of total apolipoprotein e and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
(
- Contribution to journal › Article
- 2019
-
Mark
Towards a unified protocol for handling of CSF before β-amyloid measurements
(
- Contribution to journal › Article
-
Mark
α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson’s disease patients
2019) In Proceedings of the National Academy of Sciences of the United States of America 116(30). p.15226-15235(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid concentrations of extracellular matrix proteins in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status
(
- Contribution to journal › Article
-
Mark
CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
(
- Contribution to journal › Article
- 2018
-
Mark
Amyloid blood biomarker detects Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
(
- Contribution to journal › Article
-
Mark
Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders
(
- Contribution to journal › Article
- 2017
-
Mark
Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype
(
- Contribution to journal › Article
-
Mark
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)
(
- Contribution to journal › Article
-
Mark
Concordance between different amyloid immunoassays and Visual amyloid positron emission tomographic assessment
(
- Contribution to journal › Article
-
Mark
Blood-based NfL : A biomarker for differential diagnosis of parkinsonian disorder
(
- Contribution to journal › Article
-
Mark
CSF/serum albumin ratio in dementias : a cross-sectional study on 1861 patients
(
- Contribution to journal › Article
-
Mark
Exendin-4 treatment improves LPS-induced depressive-like behavior without affecting pro-inflammatory cytokines
(
- Contribution to journal › Article
- 2016
-
Mark
The CD44 ligand hyaluronic acid is elevated in the cerebrospinal fluid of suicide attempters and is associated with increased blood-brain barrier permeability.
(
- Contribution to journal › Article
-
Mark
Plasma tau in Alzheimer disease
(
- Contribution to journal › Article
-
Mark
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios : better diagnostic markers of Alzheimer disease
(
- Contribution to journal › Article
-
Mark
CD44 Deficiency Is Associated with Increased Susceptibility to Stress-Induced Anxiety-like Behavior in Mice
(
- Contribution to journal › Article
-
Mark
Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes
(
- Contribution to journal › Article
-
Mark
Plasma β-amyloid in Alzheimer's disease and vascular disease
(
- Contribution to journal › Article
-
Mark
Author response
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson’s disease and healthy controls
(
- Contribution to journal › Article
-
Mark
Increased CSF biomarkers of angiogenesis in Parkinson disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.
(
- Contribution to journal › Article
- 2015
-
Mark
Behavioural and neurobiological consequences of macrophage migration inhibitory factor gene deletion in mice.
(
- Contribution to journal › Article
-
Mark
Increased CSF biomarkers of angiogenesis in Parkinson disease.
(
- Contribution to journal › Article
-
Mark
Low IL-8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels.
(
- Contribution to journal › Article
- 2014
-
Mark
Pro-Inflammatory Cytokines Reduce the Proliferation of NG2 Cells and Increase Shedding of NG2 In Vivo and In Vitro.
(
- Contribution to journal › Article
-
Mark
Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
(
- Contribution to journal › Article
- 2013
-
Mark
Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid inflammatory markers in Parkinson's disease - Associations with depression, fatigue, and cognitive impairment.
(
- Contribution to journal › Article
-
Mark
Connecting Inflammation with Glutamate Agonism in Suicidality
(
- Contribution to journal › Article
- 2012
-
Mark
Aldosterone synergizes with peripheral inflammation to induce brain IL-1β expression and depressive-like effects.
(
- Contribution to journal › Article
-
Mark
Toxoplasma gondii Immunoglobulin G Antibodies and Nonfatal Suicidal Self-Directed Violence
(
- Contribution to journal › Article
- 2011
-
Mark
Changes in behaviour and cytokine expression upon a peripheral immune challenge
(
- Contribution to journal › Article
-
Mark
Decreased aldosterone in the plasma of suicide attempters with major depressive disorder.
(
- Contribution to journal › Article
-
Mark
CSF biomarkers in suicide attempters - a principal component analysis.
(
- Contribution to journal › Article
-
Mark
Cytokine levels in the blood may distinguish suicide attempters from depressed patients.
(
- Contribution to journal › Article
- 2010
-
Mark
Exercise-induced release of cytokines in patients with major depressive disorder.
(
- Contribution to journal › Article
- 2009
-
Mark
Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8(+) and CD4(+) T-cells.
(
- Contribution to journal › Article
-
Mark
Immunizations With IFN gamma Secreting Tumor Cells can Eliminate Fully Established and Invasive Rat Gliomas
(
- Contribution to journal › Article
-
Mark
Interleukin-6 Is Elevated in the Cerebrospinal Fluid of Suicide Attempters and Related to Symptom Severity.
(
- Contribution to journal › Article
-
Mark
Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas.
(
- Contribution to journal › Article
- 2008
-
Mark
Experimental brain tumors, dendritic cells and immunotherapy
(
- Thesis › Doctoral thesis (compilation)
- 2007
-
Mark
Synergism between GM-CSF and IFNgamma: Enhanced immunotherapy in mice with glioma.
(
- Contribution to journal › Article
-
Mark
Inhibition of Inducible Nitric Oxide Synthase Enhances Anti-tumour Immune Responses in Rats Immunized with IFN-gamma-Secreting Glioma Cells.
(
- Contribution to journal › Article
- 2005
-
Mark
Immunization with autologous glioma cells transfected with IFN-g gene significantly prolongs survival in GBM-patients older than 50 years
2005) World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology In Neuro-Oncology 7(3). p.370-370(
- Contribution to journal › Published meeting abstract
-
Mark
Activation of purified allogeneic CD4(+) T cells by rat bone marrow-derived dendritic cells induces concurrent secretion of IFN-gamma, IL-4, and IL-10.
(
- Contribution to journal › Article
- 2002
-
Mark
Enhanced expression of iNOS intratumorally and at the immunization site after immunization with IFNgamma-secreting rat glioma cells
(
- Contribution to journal › Article
- 2001
-
Mark
Alterations of Akt1 (PKBalpha) and p70(S6K) in transient focal ischemia
(
- Contribution to journal › Article